Scientific exploitation of PAZ products in coastal surveillance and monitoring tasks

Revista oficial de la Asociación Española de Teledetección[EN] PAZ mission appears due to the need of a Spanish SAR satellite able to provide radar image products for security and defense, civil and scientific users. INTA is responsible for the technical direction of the Ground Segment, as well as the development of the Calibration and Validation Centre and the scientific exploitation. The ‘Demonstrator of Maritime SAR Applications’ is proposed as an answer to detection tasks in maritime synthetic aperture radar imagery, which are not completely solved yet. DeMSAR has been developed in the framework of a contract between the Spanish National Institute for Aerospace Technology (INTA) and the University of Alcalá. It is intended to be used as a demonstrator of the capabilities of the airborne SAR prototypes of INTA as well as for PAZ, the Spanish SAR satellite. With two operation modes, an automatic ship detector and a toolboxes mode, DeMSAR offers the user a high flexibility in SAR data processing tasks such as speckle filtering, coastline detection, land mask estimation and ship detection and characterization.[ES] La misión PAZ surge ante la necesidad de un satélite SAR español que pueda proporcionar productos imagen radar para usuarios de seguridad y defensa, civiles y científicos. INTA es el responsable de la dirección técnica del Segmento Terreno, así como del desarrollo y operación del Centro de Calibración y Validación y de la Explotación Científica. Dentro de este ámbito de explotación, se desarrolla un demostrador de aplicaciones SAR marítimas (DeMSAR) como herramienta robusta capaz de llevar a cabo tareas de detección sobre la superficie marina, empleando las imágenes adquiridas por radares de apertura sintética. Se desarrolla bajo un marco de colaboración entre el INTA y la Universidad de Alcalá con el fin de convertirse en un demostrador de las capacidades de los sistemas aerotransportados de INTA y, en el futuro, para procesar los datos adquiridos por el sensor PAZ. Con capacidad de operar en modo automático de detección de barcos o mediante librerías de procesado SAR, DeMSAR ofrece una gran versatilidad al usuario en tareas de procesado tales como filtrado de ruido speckle, detección de líneas de costa, estimación de máscaras de tierra y detección y caracterización de barcos.Jarabo, M.; González, M.; De La Mata, D.; Martín De Nicolás, J.; Del Rey, N.; Bárcena, J.; Peláez, V. (2014). Explotación científica de productos PAZ en tareas de vigilancia y monitorización costera. Revista de Teledetección. (41):97-109. doi:10.4995/raet.2014.2287.SWORD9710941Comaniciu, D., & Meer, P. (2002). Mean shift: a robust approach toward feature space analysis. IEEE Transactions on Pattern Analysis and Machine Intelligence, 24(5), 603-619. doi:10.1109/34.1000236Duda, R. O. & Hart, P. E., 1973. Pattern classification and scene analysis. Wiley.Mallat, S., 2008. A wavelet tour of signal processing. 3rd Edition. Academic Press

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

AIM: To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis. METHODS: Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis C genotype 1, treatment-nai¨ve (TN) or treatment-experienced (TE), who underwent triple therapy with the first generation NS3/4A protease inhibitors, boceprevir (BOC) and telaprevir (TVR), in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow up. RESULTS: One thousand and fifty seven patients were included, 405 (38%) were treated with BOC and 652 (62%) with TVR. Of this total, 30% (n = 319) were TN and the remaining were TE: 28% (n = 298) relapsers, 12% (n = 123) partial responders (PR), 25% (n = 260) null-responders (NR) and for 5% (n = 57) with prior response unknown. The rate of sustained virologic response (SVR) by intention-to-treatment (ITT) was greater in those treated with TVR (65%) than in those treated with BOC (52%) (P < 0.0001), whereas by modified intention-to-treatment (mITT) no were found significant differences. By degree of fibrosis, 56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients, both TN and TE. In the analysis by groups, the TN patients treated with TVR by ITT showed a higher SVR (P = 0.005). However, by mITT there were no significant differences between BOC and TVR. In the multivariate analysis by mITT, the significant SVR factors were relapsers, IL28B CC and non-F4; the type of treatment (BOC or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients, treated with BOC (46%) or with TVR (45%). 28% of the patients interrupted the treatment, mainly by non-viral response (51%): this outcome was more frequent in the TE than in the TN patients (57% vs 40%, P = 0.01). With respect to severe haematological disorders, neutropaenia was more likely to affect the patients treated with BOC (33% vs 20%, P = 0.0001), and thrombocytopaenia and anaemia, the F4 patients (P = 0.000, P = 0.025, respectively). CONCLUSION: In a real clinical practice setting with a high proportion of patients with advanced fibrosis, effectiveness of first-generation PIs was high except for NR patients, with similar SVR rates being achieved by BOC and TVR

Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID- 19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; p < 0.001), ferritin (791 (393-1534) vs. 470 (236- 996) µg/dL; p < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%